Lesinurad

CHEMBL2105720 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

404.3 g/mol

LogP

4.7

Phase

4

A uric acid transporter inhibitor for gout.

分子量

404.3000 g/mol

LogP

4.70

TPSA

93.30 Å²

リピンスキーの五則

適合

治療領域

Chronic Kidney Disease Gout

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12

InChI

InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)

Molecular Formula

C17H14BrN3O2S

HBD / HBA

1 / 5

回転可能結合数

5

重原子数

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A uric acid transporter inhibitor for gout.

Yes, Lesinurad is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105720. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 53465279. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Lesinurad PillFYIで

構造

クイックデータ

分子式: C17H14BrN3O2S

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.